Anti-FAM220A monoclonal antibody

Pre-made anti-FAM220A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to FAM220A/FAM220A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0820-Ab-1/ GM-Tg-hg-IP0820-Ab-2Anti-Human FAM220A monoclonal antibodyHuman
GM-Tg-rg-IP0820-Ab-1/ GM-Tg-rg-IP0820-Ab-2Anti-Rat FAM220A monoclonal antibodyRat
GM-Tg-mg-IP0820-Ab-1/ GM-Tg-mg-IP0820-Ab-2Anti-Mouse FAM220A monoclonal antibodyMouse
GM-Tg-cynog-IP0820-Ab-1/ GM-Tg-cynog-IP0820-Ab-2Anti-Cynomolgus/ Rhesus macaque FAM220A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0820-Ab-1/ GM-Tg-felg-IP0820-Ab-2Anti-Feline FAM220A monoclonal antibodyFeline
GM-Tg-cang-IP0820-Ab-1/ GM-Tg-cang-IP0820-Ab-2Anti-Canine FAM220A monoclonal antibodyCanine
GM-Tg-bovg-IP0820-Ab-1/ GM-Tg-bovg-IP0820-Ab-2Anti-Bovine FAM220A monoclonal antibodyBovine
GM-Tg-equg-IP0820-Ab-1/ GM-Tg-equg-IP0820-Ab-2Anti-Equine FAM220A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0820-Ab-1/ GM-Tg-hg-IP0820-Ab-2; GM-Tg-rg-IP0820-Ab-1/ GM-Tg-rg-IP0820-Ab-2;
GM-Tg-mg-IP0820-Ab-1/ GM-Tg-mg-IP0820-Ab-2; GM-Tg-cynog-IP0820-Ab-1/ GM-Tg-cynog-IP0820-Ab-2;
GM-Tg-felg-IP0820-Ab-1/ GM-Tg-felg-IP0820-Ab-2; GM-Tg-cang-IP0820-Ab-1/ GM-Tg-cang-IP0820-Ab-2;
GM-Tg-bovg-IP0820-Ab-1/ GM-Tg-bovg-IP0820-Ab-2; GM-Tg-equg-IP0820-Ab-1/ GM-Tg-equg-IP0820-Ab-2
Products NameAnti-FAM220A monoclonal antibody
Formatmab
Target NameFAM220A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-FAM220A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0820-Ag-1Recombinant multi-species F220A/ FAM220A/ ACPIN1 protein


    Target information

    Target IDGM-IP0820
    Target NameFAM220A
    Gene ID84792,67238,498145,703785,123382727,100061834
    Gene Symbol and Synonyms1500026F15Rik,2810453I06Rik,ACPIN1,C7orf70,FAM220A,SIPAR
    Uniprot AccessionQ7Z4H9,Q6DGF6
    Uniprot Entry NameF220A_HUMAN,F220A_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000178397
    Target ClassificationN/A

    The target: FAM220A, gene name: FAM220A, also named as ACPIN1, C7orf70, SIPAR. Predicted to enable STAT family protein binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II and protein dephosphorylation. Predicted to act upstream of or within positive regulation of protein binding activity. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.